{ "meta": { "data_length": 2, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A92", "status": "success", "status_code": 200, "timestamp_elapsed": 0.00477, "timestamp_received": "2026-09-25T01:16:33.688194+00:00Z", "timestamp_returned": "2026-09-25T01:16:33.692964+00:00Z", "trace_id": "62d3735a-3427-4f6e-8b9c-5807f49f7dbb" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:tafinlar:4:0", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2018-05-04:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2018-05-04", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:tafinlar", "type": "Document", "documentType": "Regulatory approval", "name": "Tafinlar (dabrafenib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tafinlar", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "dabrafenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 202806, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-29", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:92", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:THAP", "conceptType": "Disease", "name": "Anaplastic Thyroid Cancer", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:THAP", "code": "THAP", "name": "Anaplastic Thyroid Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THAP" ] } }, "objectTherapeutic": { "id": "txgrp:18", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C82386", "conceptType": "Therapy", "name": "Dabrafenib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1424911", "code": "1424911", "name": "dabrafenib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1424911" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43532299", "code": "43532299", "name": "dabrafenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43532299" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:703641001", "code": "703641001", "name": "Dabrafenib", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=703641001&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:45766476", "code": "45766476", "name": "Dabrafenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/45766476" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "B-RAF inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386" ] } }, { "id": "tx:ncit:C77908", "conceptType": "Therapy", "name": "Trametinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1425099", "code": "1425099", "name": "trametinib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1425099" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43532497", "code": "43532497", "name": "trametinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43532497" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:708711009", "code": "708711009", "name": "Trametinib", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=708711009&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:46270750", "code": "46270750", "name": "Trametinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/46270750" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "MEK inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:16", "present": true, "subject": { "id": "bmkr:16", "type": "CategoricalVariant", "name": "BRAF p.V600E", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "name": "NP_004324.2:p.Val600Glu", "aliases": [ "NP_004324.2:p.V600E", "BRAF p.V600E" ], "description": "VRS variation of NP_004324.2:p.Val600Glu", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "expressions": [ { "syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu", "extensions": [ { "name": "hgvs.p_short", "value": "p.V600E" } ] } ], "location": { "id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 600 of the Refseq protein NP_004324.2, which is the protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6).", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": { "id": "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "type": "SequenceReference", "name": "NP_004324.2", "aliases": [ "ensembl:ENSP00000288602.6", "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "refseq:NP_004324.2" ], "description": "The protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6), corresponding to the Refseq protein accession NP_004324.2.", "moleculeType": "protein", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "residueAlphabet": "aa" }, "start": 599, "end": 600, "sequence": "V" }, "state": { "type": "LiteralSequenceExpression", "sequence": "E" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:1097", "conceptType": "Gene", "name": "BRAF", "primaryCoding": { "id": "coding:hgnc:1097", "code": "HGNC:1097", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000157764", "code": "ENSG00000157764", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000157764" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:673", "code": "673", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/673" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004333.6", "code": "NM_004333.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "7" }, { "name": "start_position", "value": 140453136 }, { "name": "end_position", "value": 140453136 }, { "name": "reference_allele", "value": "A" }, { "name": "alternate_allele", "value": "T" }, { "name": "cdna_change", "value": "c.1799T>A" }, { "name": "protein_change", "value": "p.V600E" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 15 }, { "name": "rsid", "value": "rs113488022" }, { "name": "hgvsg", "value": "7:g.140453136A>T" }, { "name": "hgvsc", "value": "ENST00000288602.6:c.1799T>A" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:tafinlar:4", "type": "Indication", "description": "TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2018-05-04:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2018-05-04", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:tafinlar", "type": "Document", "documentType": "Regulatory approval", "name": "Tafinlar (dabrafenib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tafinlar", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "dabrafenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 202806, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-29", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] }, { "id": "stmt:fda:mekinist:4:0", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:fda:mekinist", "type": "Document", "documentType": "Regulatory approval", "name": "Mekinist (trametinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Mekinist", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "trametinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 217513, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-29", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:92", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:THAP", "conceptType": "Disease", "name": "Anaplastic Thyroid Cancer", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:THAP", "code": "THAP", "name": "Anaplastic Thyroid Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THAP" ] } }, "objectTherapeutic": { "id": "txgrp:18", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C82386", "conceptType": "Therapy", "name": "Dabrafenib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1424911", "code": "1424911", "name": "dabrafenib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1424911" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43532299", "code": "43532299", "name": "dabrafenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43532299" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:703641001", "code": "703641001", "name": "Dabrafenib", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=703641001&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:45766476", "code": "45766476", "name": "Dabrafenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/45766476" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "B-RAF inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386" ] } }, { "id": "tx:ncit:C77908", "conceptType": "Therapy", "name": "Trametinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1425099", "code": "1425099", "name": "trametinib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1425099" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43532497", "code": "43532497", "name": "trametinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43532497" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:708711009", "code": "708711009", "name": "Trametinib", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=708711009&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:46270750", "code": "46270750", "name": "Trametinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/46270750" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "MEK inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:16", "present": true, "subject": { "id": "bmkr:16", "type": "CategoricalVariant", "name": "BRAF p.V600E", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "name": "NP_004324.2:p.Val600Glu", "aliases": [ "NP_004324.2:p.V600E", "BRAF p.V600E" ], "description": "VRS variation of NP_004324.2:p.Val600Glu", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "expressions": [ { "syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu", "extensions": [ { "name": "hgvs.p_short", "value": "p.V600E" } ] } ], "location": { "id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 600 of the Refseq protein NP_004324.2, which is the protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6).", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": { "id": "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "type": "SequenceReference", "name": "NP_004324.2", "aliases": [ "ensembl:ENSP00000288602.6", "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "refseq:NP_004324.2" ], "description": "The protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6), corresponding to the Refseq protein accession NP_004324.2.", "moleculeType": "protein", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "residueAlphabet": "aa" }, "start": 599, "end": 600, "sequence": "V" }, "state": { "type": "LiteralSequenceExpression", "sequence": "E" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:1097", "conceptType": "Gene", "name": "BRAF", "primaryCoding": { "id": "coding:hgnc:1097", "code": "HGNC:1097", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000157764", "code": "ENSG00000157764", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000157764" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:673", "code": "673", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/673" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004333.6", "code": "NM_004333.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "7" }, { "name": "start_position", "value": 140453136 }, { "name": "end_position", "value": 140453136 }, { "name": "reference_allele", "value": "A" }, { "name": "alternate_allele", "value": "T" }, { "name": "cdna_change", "value": "c.1799T>A" }, { "name": "protein_change", "value": "p.V600E" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 15 }, { "name": "rsid", "value": "rs113488022" }, { "name": "hgvsg", "value": "7:g.140453136A>T" }, { "name": "hgvsc", "value": "ENST00000288602.6:c.1799T>A" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:mekinist:4", "type": "Indication", "description": "MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:fda:mekinist", "type": "Document", "documentType": "Regulatory approval", "name": "Mekinist (trametinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Mekinist", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "trametinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 217513, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-29", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }